NVCR NovoCure Ltd
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1645113 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY12.9%
TTM net income YoY31.5%
TTM EPS YoY34.2%
Revenue 3-yr CAGR12.9%
Net income 3-yr CAGR—
Margins
Gross margin77.0%
Operating margin-17.2%
Net margin-16.8%
FCF margin-3.4%
EBITDA margin-14.8%
Returns
ROE-35.2%
ROA-11.1%
ROIC (approx.)-77.8%
Asset turnover0.66x
Leverage & solvency
Liabilities / assets57.7%
Debt / equity0.00x
Current ratio2.49x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.01x
Accruals ratio-11.1%
Payout ratio—
Capex / revenue3.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $655.35M | $605.22M | $509.34M | $537.84M | $535.03M |
| Cost of revenue | $166.88M | $137.18M | $128.28M | $114.87M | $114.88M |
| Gross profit | $488.47M | $468.04M | $381.06M | $422.97M | $420.15M |
| R&D expense | $224.54M | $209.65M | $223.06M | $206.09M | $201.30M |
| SG&A expense | $177.67M | $189.83M | $164.06M | $132.75M | $126.13M |
| Operating income | -$153.80M | -$170.50M | -$232.87M | -$89.52M | -$44.33M |
| Interest expense | $22.22M | $11.66M | $4.91M | $8.11M | $8.84M |
| Pretax income | -$136.25M | -$131.16M | -$191.74M | -$81.85M | -$52.08M |
| Income tax | -$23,000 | $37.47M | $15.30M | $10.69M | $6.28M |
| Net income | -$136.23M | -$168.63M | -$207.04M | -$92.53M | -$58.35M |
| EBITDA | -$139.15M | -$159.26M | -$221.90M | -$78.90M | -$34.08M |
| EPS (basic) | -1.22 | -1.56 | -1.95 | -0.88 | -0.56 |
| EPS (diluted) | -1.22 | -1.56 | -1.95 | -0.88 | -0.56 |
| Weighted avg. shares (diluted) | 111.47M | 107.83M | 106.39M | 104.66M | 103.43M |
| Balance sheet | |||||
| Cash & equivalents | $93.55M | $166.09M | $240.82M | $115.83M | $209.61M |
| Receivables | $89.44M | $74.23M | $61.22M | $86.26M | $93.57M |
| Inventory | $41.11M | $35.09M | $38.15M | $29.38M | $24.43M |
| Current assets | $646.73M | $1.11B | $1.03B | $1.11B | $1.07B |
| PP&E, net | $77.61M | $77.66M | $51.48M | $32.68M | $22.69M |
| Total assets | $804.33M | $1.24B | $1.15B | $1.19B | $1.14B |
| Current liabilities | $223.23M | $756.39M | $179.12M | $158.78M | $142.60M |
| Short-term debt | $0 | — | — | — | — |
| Long-term debt | $195.05M | $97.30M | $568.82M | $565.51M | $562.22M |
| Total debt | $195.05M | $97.30M | $568.82M | $565.51M | $562.22M |
| Total liabilities | $463.86M | $880.61M | $783.63M | $750.48M | $729.00M |
| Shareholders' equity | $340.47M | $360.18M | $362.50M | $441.17M | $410.49M |
| Net debt | $101.50M | -$68.79M | $328.00M | $449.68M | $352.61M |
| Shares outstanding | 112.49M | 108.52M | 107.08M | 105.05M | 103.97M |
| Cash flow statement | |||||
| Operating cash flow | -$49.03M | -$26.37M | -$73.34M | $30.79M | $82.76M |
| Capital expenditure | $26.65M | $42.85M | $27.09M | $21.36M | $24.17M |
| Free cash flow | -$75.68M | -$69.22M | -$100.43M | $9.43M | $58.59M |
| Investing cash flow | $437.28M | -$140.24M | $184.15M | -$139.96M | -$144.83M |
| Financing cash flow | -$451.34M | $90.31M | $15.79M | $15.49M | $25.70M |
| Depreciation & amortization | $14.65M | $11.23M | $10.97M | $10.62M | $10.25M |
| Stock-based compensation | $104.83M | $160.03M | $115.61M | $106.95M | $94.90M |
Free plan shows the latest 5 periods; Pro shows all 13 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.